Read and download below our recent news and media releases
Endo-PAT system may help measure cardiovascular risk from breast cancer treatment
Itamar Medical - Head Office, 8 January 2017
SAN ANTONIO — The Endo-PAT2000 assay may be a simple way to measure vascular elasticity in outpatients after treatment with aromatase inhibitors, Douglas Yee, MD, director of the Masonic Cancer Center, professor of medicine and pharmacology at the University of Minnesota, and a HemOnc Today Editorial Board member, told HemOnc Today at the San Antonio Breast Cancer Symposium.
FDA Clears Expanded Indication for Itamar Medical's WatchPAT Sleep Apnea Diagnostic Device for Adolescents
Itamar Medical - Head Office, 27 July 2016
Itamar Medical Reports Success in Clinical Study Validating WatchPAT for Central Sleep Apnea Differentiation, Submits Application for FDA Clearance of New WatchPAT Version
Itamar Medical - Head Office, 9 June 2016
Itamar Medical Offers a Total Sleep Apnea Management Solution to Cardiologists
Itamar Medical - Head Office, 13 May, 2015
Marketing Bulletin: Canada Youth WatchPAT
Itamar Medical - Head Office, 12 April 2016
EndoPAT distributor in China - Important Notice
Head Office, 26 April 2015
NEW EndoPAT exclusive distributor for the Chinese market.
Itamar Medical Launches WatchPAT Unified
Head Office, 09 June 2014
Click here to view Press Release
Itamar Medical's EndoPAT Featured on the Doctor's Channel
Head Office, 02 Mar 2014
Gilad Glick, CEO, Itamar Medical, introduces the Endopat 2000, an innovative device that can assess cardiac health in 15 minutes.
Itamar Medical Ltd.
9 Halamish Street,
Caesarea, 3088900 Israel